Gemfibrozil

證據等級: L5

預測適應症: 10 個

Gemfibrozil: From Dyslipidemia to Rheumatoid Arthritis

One-Sentence Summary

Gemfibrozil is a fibric acid derivative and PPARα agonist, widely used for the management of dyslipidemia — particularly hypertriglyceridemia and mixed lipid disorders. The TxGNN model predicts it may be effective for Rheumatoid Arthritis through its anti-inflammatory and immunomodulatory properties, with 0 clinical trials and 4 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Dyslipidemia / Hypertriglyceridemia
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	99.90%
Evidence Level	L4
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Gemfibrozil is a fibric acid derivative that activates PPARα (Peroxisome Proliferator-Activated Receptor alpha). Although formal MOA data is not available in this evidence pack, it is well established that PPARα activation suppresses the NF-κB signaling pathway, thereby reducing key pro-inflammatory cytokines — TNF-α, IL-6, and IL-1β — which are central to rheumatoid arthritis (RA) pathogenesis. This anti-inflammatory mechanism extends well beyond lipid metabolism, providing a biologically plausible mechanistic bridge to immune-mediated joint disease.

The connection between dyslipidemia and RA is not incidental. Systemic inflammation in RA contributes to lipid dysregulation, and conversely, elevated inflammatory cytokines perpetuate metabolic dysfunction. A 2019 rat adjuvant-induced arthritis study (PMID 30074417) showed that gemfibrozil combined with a reduced prednisolone dose produced outcomes comparable to full-dose steroid therapy, suggesting a potential steroid-sparing effect. A 2026 animal study with bezafibrate — a pan-PPAR agonist in the same fibrate class — further demonstrated attenuation of experimental RA through PPAR-γ-dependent suppression of inflammatory pathways (PMID 41207105), supporting a class-level anti-arthritic mechanism.

Additionally, a mechanistic study (PMID 20083653) demonstrated that nitric oxide reduces Foxp3 expression in regulatory T cells (Tregs) during autoimmune priming — and PPARα activation may counteract this pathway, offering a further immunomodulatory rationale. However, all existing evidence is preclinical; no human clinical trials have validated this repurposing hypothesis in RA patients.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30074417	2019	Animal Study	Modern Rheumatology	Gemfibrozil (30 mg/kg) combined with reduced-dose prednisolone showed comparable efficacy to full-dose prednisolone in a rat adjuvant-induced arthritis model; supports a potential steroid-sparing role via PPARα activation
41207105	2026	Animal Study	Int Immunopharmacology	Bezafibrate (pan-PPAR agonist, same fibrate class) attenuated experimental RA via PPAR-γ-dependent suppression of inflammatory pathways; molecular docking identified fibrates as PPAR-γ agonists with anti-arthritic potential
20083653	2010	Mechanistic Study	J Immunology	Nitric oxide suppresses Foxp3 expression in regulatory T cells during autoimmune priming; PPARα signaling may preserve Treg function in autoimmune conditions
18039017	2007	Review	Am J Clin Dermatology	Overview of palmar erythema associated with systemic conditions including RA; limited direct relevance to gemfibrozil pharmacology

Singapore Market Information

Gemfibrozil currently holds no product registrations in Singapore and is not marketed in this market. No licensed dosage forms or approved indications are on record.

Safety Considerations

Please refer to the package insert for safety information.

⚠️ Note from evidence review: Literature identified in the HIV-dyslipidemia indication (Rank 3) flags a clinically significant interaction risk: concurrent use of gemfibrozil with statins (e.g., cerivastatin) has been associated with rhabdomyolysis in HIV-infected patients (PMID 11371708). This interaction risk should be specifically evaluated before any RA repurposing pathway, as RA patients frequently receive statins for cardiovascular risk reduction.

Conclusion and Next Steps

Decision: Hold

Rationale: All current evidence for gemfibrozil in rheumatoid arthritis is preclinical (animal models and mechanistic studies only); no human clinical trials have been registered or completed. While the PPARα-mediated anti-inflammatory mechanism is biologically coherent and supported by fibrate class data, the complete absence of clinical validation, combined with the drug's non-marketed status in Singapore, places this firmly in the research hypothesis stage.

To proceed, the following is needed:

Retrieve full package insert from a registered market (e.g., US FDA or EMA) to document key warnings, contraindications, and musculoskeletal adverse effects
Obtain formal MOA data from DrugBank (DB01241) to substantiate the NF-κB/PPARα mechanistic rationale
Conduct a human proof-of-concept study or Phase 1/2 clinical trial in RA patients, ideally in a population with comorbid dyslipidemia where dual benefit may be achieved
Evaluate drug interaction risk profile with common RA treatments (methotrexate, hydroxychloroquine, JAK inhibitors, TNF biologics)
Assess pharmacokinetics relevant to joint tissue penetration and synovial fluid exposure
If Phase 1/2 data is supportive, pursue Singapore HSA registration as a prerequisite for local clinical development
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.